IO102 + IO103 + Montanide clinical trials

Activity and safety of peptide-based immunotherapy in an umbrella window of opportunity phase II study in patients with squamous cell carcinoma of the head and neck.

This study is looking at new treatments for head and neck cancer. It tests three different approaches using special vaccines (IO103, IO102, or both) to see how safe and effective they are. The aim is to help the body's immune system fight the cancer.